UBS Downgrades Apogee Therapeutics Inc (APGE) to Neutral

June 23, 2026 3:07 AM

UBS analyst Michael Yee downgraded Apogee Therapeutics Inc (NASDAQ: APGE) from Buy to Neutral with a price target of $135.11 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found